Streptococcus pneumoniae type 5 capsular polysaccharide antigen
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Streptococcus pneumoniae type 5 capsular polysaccharide antigen
- Accession Number
- DB10323
- Description
Streptococcus pneumoniae type 5 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 5 of Streptococcus pneumoniae. It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Vaccines
Other vaccines - Synonyms
- pneumococcal capsular polysaccharide type 5 vaccine
Pharmacology
- Indication
- Not Available
- Associated Conditions
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Mixture Products
Categories
- Drug Categories
- Classification
- Not classified
Chemical Identifiers
- UNII
- N8R9GL539D
- CAS number
- Not Available
References
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Prevention Acute Lymphoblastic Leukaemias (ALL) 1 4 Active Not Recruiting Prevention Chronic Kidney Disease (CKD) 1 4 Active Not Recruiting Prevention Rheumatoid Arthritis / Sjögren's Syndrome / Spondyloarthritis / Systemic Lupus / Systemic Vasculitis 1 4 Completed Diagnostic Crohn's Disease (CD) 1 4 Completed Diagnostic Immune Response / Pneumonia / Streptococcus Pneumoniae 1 4 Completed Prevention Asthma 2 4 Completed Prevention BCG Infection / Immune Response / Reaction - Vaccine 1 4 Completed Prevention Bone Marrow Transplant (BMT) 1 4 Completed Prevention Chronic Obstructive Pulmonary Disease (COPD) 1 4 Completed Prevention Chronic Plaque Psoriasis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Intramuscular; Subcutaneous 25 mcg/0.5mL Solution Intramuscular; Subcutaneous 25 mcg Injection, solution Intramuscular; Subcutaneous Solution Intramuscular; Subcutaneous Injection, solution Subcutaneous 25 μg Injection, solution Intramuscular; Subcutaneous 25 ug/0.5mL Injection, suspension Intramuscular 2.2 mcg/0.5mL Injection, suspension Intramuscular 34 mcg/0.5mL Suspension Intramuscular Injection Intramuscular 1 µg Injection, suspension Intramuscular 1 µg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on December 01, 2015 13:03 / Updated on June 12, 2020 10:53